X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2177) 2177
Publication (230) 230
Book Review (21) 21
Book Chapter (5) 5
Dissertation (4) 4
Book / eBook (2) 2
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1849) 1849
index medicus (1226) 1226
female (972) 972
male (964) 964
quinazolines - pharmacokinetics (937) 937
oncology (854) 854
animals (773) 773
quinazolines - pharmacology (726) 726
quinazolines - administration & dosage (687) 687
quinazolines - therapeutic use (686) 686
middle aged (645) 645
pharmacology & pharmacy (611) 611
adult (584) 584
aged (573) 573
quinazolines - adverse effects (531) 531
gefitinib (419) 419
pharmacokinetics (416) 416
mice (408) 408
cancer (378) 378
erlotinib hydrochloride (356) 356
lung neoplasms - drug therapy (350) 350
receptor, epidermal growth factor - antagonists & inhibitors (343) 343
dose-response relationship, drug (335) 335
antineoplastic agents - therapeutic use (329) 329
antineoplastic agents - pharmacokinetics (328) 328
tyrosine kinase inhibitor (327) 327
treatment outcome (321) 321
carcinoma, non-small-cell lung - drug therapy (320) 320
erlotinib (318) 318
cell line, tumor (294) 294
chemotherapy (288) 288
antineoplastic agents - pharmacology (272) 272
cell lung-cancer (264) 264
antineoplastic combined chemotherapy protocols - therapeutic use (256) 256
growth-factor receptor (248) 248
rats (246) 246
neoplasms - drug therapy (236) 236
quinazolines - chemistry (234) 234
administration, oral (229) 229
protein kinase inhibitors - pharmacology (219) 219
protein kinase inhibitors - therapeutic use (213) 213
antineoplastic agents - adverse effects (206) 206
quinazolines - blood (206) 206
egfr (202) 202
research (201) 201
chemistry, medicinal (195) 195
protein kinase inhibitors - pharmacokinetics (192) 192
care and treatment (191) 191
medicine & public health (186) 186
therapy (183) 183
aged, 80 and over (180) 180
antineoplastic agents - administration & dosage (176) 176
tumors (173) 173
drug therapy (169) 169
analysis (164) 164
pharmacology/toxicology (163) 163
expression (160) 160
mutation (159) 159
area under curve (154) 154
receptor, epidermal growth factor - metabolism (153) 153
epidermal growth factor (152) 152
lung neoplasms - pathology (150) 150
drug administration schedule (145) 145
drug interactions (142) 142
antineoplastic combined chemotherapy protocols - adverse effects (136) 136
article (136) 136
inhibitor (136) 136
lapatinib (136) 136
trial (135) 135
breast neoplasms - drug therapy (134) 134
quinazolines - metabolism (133) 133
receptor, epidermal growth factor - genetics (132) 132
protein kinase inhibitors - administration & dosage (128) 128
tissue distribution (128) 128
breast cancer (127) 127
solid tumors (127) 127
maximum tolerated dose (126) 126
structure-activity relationship (126) 126
protein kinase inhibitors - adverse effects (125) 125
carcinoma, non-small-cell lung - pathology (124) 124
tyrosine (123) 123
antineoplastic combined chemotherapy protocols - pharmacokinetics (122) 122
lung cancer, non-small cell (122) 122
mice, nude (121) 121
clinical trials as topic (118) 118
lung cancer (118) 118
pharmacology (116) 116
cancer research (115) 115
quinazolines - chemical synthesis (115) 115
phase-i (114) 114
xenograft model antitumor assays (114) 114
clinical trials (113) 113
cell proliferation - drug effects (112) 112
kinases (110) 110
tyrosine kinase inhibitors (110) 110
breast-cancer (109) 109
biological availability (107) 107
combination (105) 105
health aspects (105) 105
antineoplastic agents (104) 104
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2150) 2150
Chinese (12) 12
French (9) 9
German (5) 5
Japanese (5) 5
Spanish (3) 3
Danish (2) 2
Hungarian (2) 2
Italian (2) 2
Bulgarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
Summary In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment and numerous are under investigation. These drugs... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-CELL CARCINOMA | CHRONIC MYELOID-LEUKEMIA | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHRONIC MYELOCYTIC-LEUKEMIA | ADVANCED SOLID MALIGNANCIES | IMATINIB MESYLATE GLEEVEC | GASTROINTESTINAL STROMAL TUMORS | CEREBROSPINAL-FLUID PHARMACOKINETICS | CANCER RESISTANCE PROTEIN | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 06/2010, Volume 333, Issue 3, pp. 788 - 796
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 3/2017, Volume 56, Issue 3, pp. 235 - 250
Afatinib is an oral, irreversible ErbB family blocker that covalently binds to the kinase domains of epidermal growth factor receptor (EGFR), human EGFRs (HER)... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | CELL LUNG-CANCER | BREAST-CANCER | RANDOMIZED PHASE-3 TRIAL | BIBW 2992 | ADVANCED SOLID TUMORS | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | PHARMACOLOGY & PHARMACY | OPEN-LABEL | ERBB FAMILY BLOCKER | I DOSE-ESCALATION | Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Kidney - drug effects | Humans | Liver - metabolism | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Quinazolines - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Radiation-Sensitizing Agents - pharmacokinetics | Neoplasms - drug therapy | Radiation-Sensitizing Agents - therapeutic use | ATP-Binding Cassette, Sub-Family B, Member 1 - agonists | Kidney - metabolism | Receptor, Epidermal Growth Factor - metabolism | Animals | Liver - drug effects | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Drug Interactions - physiology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Binding - physiology | Pharmacology | Research | Bioavailability | Pharmacokinetics | Analysis | Cytochrome | Plasma | Lung cancer | Breast cancer | Metastasis | Permeability | Kinases | Cancer therapies | Studies | Chemotherapy | Epidermal growth factor | Mutation | Drug dosages | Binding sites | Tumors | Review
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2014, Volume 74, Issue 1, pp. 95 - 115
This study evaluated the preclinical pharmacokinetics (PK) and disposition of Fruquintinib (HMPL-013), a small molecule vascular endothelial growth factor... 
Fruquintinib | Medicine & Public Health | Disposition | Oncology | Cancer Research | HMPL-013 | Pharmacology/Toxicology | Pharmacokinetics | Allometric scaling | Modeling | HALF-LIFE | NONSPECIFIC-BINDING | CLEARANCE | FACTOR RECEPTORS | PROTEIN-BINDING | IN-VITRO | POTENT | ONCOLOGY | DRUGS | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | ENDOTHELIAL GROWTH-FACTOR | Inactivation, Metabolic | Drugs, Investigational - pharmacology | Cytochrome P-450 Enzyme Inhibitors | Bile - chemistry | Humans | Microsomes, Liver - metabolism | Drugs, Investigational - pharmacokinetics | Cytochrome P-450 Enzyme System - metabolism | Quinazolines - pharmacokinetics | Benzofurans - administration & dosage | Benzofurans - pharmacology | Biological Availability | Male | Drugs, Investigational - metabolism | Intestinal Absorption | Benzofurans - pharmacokinetics | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Drug Interactions | Quinazolines - metabolism | Microsomes, Liver - drug effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Quinazolines - administration & dosage | Microsomes, Liver - enzymology | Drug Evaluation, Preclinical | Caco-2 Cells | Protein Kinase Inhibitors - pharmacokinetics | Food-Drug Interactions | Cells, Cultured | Angiogenesis Inhibitors - pharmacology | Angiogenesis Inhibitors - pharmacokinetics | Random Allocation | Protein Kinase Inhibitors - administration & dosage | Angiogenesis Inhibitors - metabolism | Animals | Models, Biological | Drugs, Investigational - administration & dosage | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Benzofurans - metabolism | Protein Kinase Inhibitors - metabolism | Physiological aspects | Permeability | Metabolites | Vascular endothelial growth factor | Gastrointestinal system | Protein binding
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 12/2010, Volume 49, Issue 12, pp. 829 - 840
Linagliptin (BI 1356) is a highly specific inhibitor of dipeptidyl peptidase (DPP)-4, which is currently in phase III clinical development for the treatment of... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Research-and-development | Population-pharmacokinetics | Antihyperglycaemics, pharmacokinetics | Linagliptin, pharmacokinetics | Bioavailability | Dipeptidyl-peptidase-inhibitors, pharmacodynamics | Pharmacokinetic-pharmacodynamic-relationships | Linagliptin, pharmacodynamics | Pharmacokinetic-modelling | Dipeptidyl-peptidase-inhibitors, pharmacokinetics | Antihyperglycaemics, pharmacodynamics | TARGET | MEDIATED DRUG DISPOSITION | TYPE-2 DIABETIC-PATIENTS | PLASMA | GLUCAGON-LIKE PEPTIDE-1 | TOLERABILITY | VOLUNTEERS | PHARMACOLOGY & PHARMACY | PROTEIN BINDING | BENAZEPRILAT | POLYPEPTIDE | Single-Blind Method | Dipeptidyl Peptidase 4 - metabolism | Tablets | Area Under Curve | Humans | Middle Aged | Half-Life | Quinazolines - pharmacokinetics | Biological Availability | Male | Purines - administration & dosage | Dose-Response Relationship, Drug | Tissue Distribution | Young Adult | Quinazolines - metabolism | Adult | Dipeptidyl-Peptidase IV Inhibitors - metabolism | Quinazolines - administration & dosage | Linagliptin | Purines - metabolism | Purines - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Cross-Over Studies | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Models, Biological | Adolescent | Protein Binding | Infusions, Intravenous | Type 2 diabetes | Complications and side effects | Hypoglycemic agents | Dosage and administration | Research | Pharmacokinetics | Drug therapy
Journal Article